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Background: Tobramycin inhalation is an accepted treatment of chronic pseudomonal infection in cystic ﬁbrosis (CF) patients. Twice daily
inhalation is efﬁcacious, but time-consuming.
Methods: In this randomized, open-label, multicentre, two-period, crossover study, 58 patients with CF and chronic Pseudomonas aeruginosa (PA)
infection received two tobramycin nebuliser solutions: T100/eFlow or TNS/PARI LC PLUS. The primary objective was to demonstrate the
equivalence of both treatments with respect to pharmacokinetics (area under the concentration–time curve and maximum concentration in plasma).
Secondary endpoints were tobramycin sputum pharmacokinetics, reduction in PA colony forming units, improvement of lung function, incidence
of adverse drug reactions and reduction of inhalation times.
Results: Tobramycin plasma AUC and Cmax were lower after administration of T100 than after TNS. The study failed to demonstrate systemic
bioequivalence of the two treatments. After T100 administration, tobramycin sputum AUC and Cmax achieved higher values than after TNS.
Changes in efﬁcacy parameters from baseline were similar. Safety proﬁles were not different or unexpected. Inhalation time per inhalation was
shorter during treatment with T100.
Conclusion: The lower systemic drug burden and the higher local drug deposition together with a comparable efﬁcacy/safety proﬁle and a shorter
inhalation time render T100/eFlow an attractive treatment option for CF patients.
(www.controlled-trials.com/ISRCTN85410458).
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For the treatment of CF patients chronically infected with
Pseudomonas aeruginosa (PA), use of tobramycin solutions
for inhalation offers deposition of high local antibiotic drug☆ Previous presentation of data. Summaries of the results of this trial have been
presented previously as posters at the 36th European Cystic Fibrosis Conference
(ECFC), 12–15 June 2013, Lisbon, Portugal and the 23rd Annual Congress of the
European Respiratory Society (ERS), 7–11 September 2013, Barcelona, Spain.
⁎ Corresponding author. Tel.: +48 22 32 77 371; fax: +48 22 32 77 043.
E-mail address: dorotasands@rubikon.pl (D. Sands).
http://dx.doi.org/10.1016/j.jcf.2014.04.006
1569-1993/© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. Aconcentrations at the site of infection, whilst limiting organ
toxicities because of minimized systemic exposure. Twice daily
inhalation of tobramycin nebuliser solution (TNS) has been
established as standard-of-care therapy [1,2]. Nebulisation of large
volumes using standard jet nebulisers powered by a table top
compressor is time-consuming and one procedure may take
15 min or more. Increase of drug concentration, thus reducing
the volume, and use of an efficient nebuliser allow a substantial
reduction of the nebulisation time. PARI Pharma GmbH has
developed a concentrated tobramycin solution (T100) and a
drug-specific nebuliser based on the eFlow technology.ll rights reserved.
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alence of the efficient drug/device combination T100 to standard
TNS regarding tobramycin pharmacokinetics in plasma as well as
to compare sputum pharmacokinetics and clinical efficacy and
safety.2. Methods
2.1. Study subjects
CF patients were eligible for participation if they were
≥4 years of age, had confirmed cystic fibrosis (one or more
clinical features and sweat chloride ≥ 60 mEq/l by quantitative
pilocarpine iontophoresis test and/or presence of disease-associated
CF transmembrane conductance regulator mutations in both allels),
FEV1 % predicted of N25% and ≤85% at screening, confirmed
chronic PA lung infection and were able to produce sputum and to
perform lung function tests. Besides general criteria excluding
patients from study participation, study-specific exclusion criteria
were: hypersensitivity to inhaled or systemic aminoglycosides,
anti-pseudomonal aminoglycoside therapy within 30 days or
other antibiotic therapy within 7 days prior to first study drug
administration, haemoptysis, positive Burkholderia cepacia cul-
ture, presence of allergic bronchopulmonary aspergillosis or other
severe respiratory infections and auditory/vestibular dysfunctions.
Written informed consent was obtained from all patients or legal
representatives.2.2. Study design
This study was a prospective, multicentre, open-label, random-
ized, two-period, crossover study comparing the new formulation
of T100 with the registered standard TNS.
T100, the new formulation of tobramycin (VANTOBRA,
170 mg tobramycin/1.7 ml; PARI Pharma GmbH, Starnberg,
Germany), was delivered via a drug-specific efficient eFlow
technology nebuliser handset (Tolero, operated with an eBase
controller; PARI Pharma GmbH, Starnberg, Germany). TNS
(TOBI; 300 mg tobramycin/5 ml; Novartis, Basle, Switzerland)
was administered using the PARI LC PLUS nebuliser in com-
bination with the PARI BOY SX compressor (PARI GmbH,
Starnberg, Germany).
After informed consent was obtained, screening tests to
establish patient eligibility were performed within one week before
first study drug administration. Patient stratification according to
age (4–13 or N13 years) and 1:1-randomization were done
immediately pre-dose on Day 1 of Treatment Period-1. Study
medication was inhaled twice daily as add-on therapy to existing
medication for a period of 4 weeks, followed by a 4-week
wash-out phase and a crossover to the comparator for another
4-week Treatment Period-2. After completion of the second
treatment, patients were observed for 1 week for safety reasons.
The study, which was approved by the ethics committees of
each participating centre, was conducted according to the ethical
principles of the Declaration of Helsinki.2.3. Determination of FEV1 % predicted
Lung function tests were standardized and performed accord-
ing to the recommendations of the American Thoracic Society
(ATS)/European Respiratory Society (ERS) [3].
2.4. Evaluation of pharmacokinetics
On the last day of each treatment period blood samples
(3–4 ml) for the assessment of tobramycin concentrations were
collected in lithium-heparin tubes 30–15 min prior to inhalation,
30, 60, and 90 min and 2, 4, 6, 8 and 12 h after the end of
inhalation. For the assessment of tobramycin sputum concentra-
tions, sputum samples were collected in sterile culture dishes 30–
15 min prior to inhalation, 10, 30, and 90 min and 2 and 8 h after
the end of inhalation on the last treatment day. Tobramycin
concentrations were determined using reversed phase HPLC–
MS/MS after electrospray ionization. The method was validated
with a lower limit of quantification of 30 ng/ml.
2.5. Evaluation of compliance and nebulisation time
Compliance and nebulisation time were determined by diaries
completed by the patients for TNS and by electronic recording
via chip cards incorporated into the patient monitoring systems
for T100. The chip cards recorded date, time and duration of each
nebulisation session together with the cause for termination.
Compliance was calculated as the ratio of actual to planned
inhalations and was depicted graphically per study day and as
cumulative compliance from the start until completion of the
treatment period.
2.6. Evaluation of safety
The incidence of treatment-emerged adverse events was
recorded throughout the complete study period, including
abnormal clinical laboratory results with emphasis on voice
alterations, signs of tinnitus and bronchospasms. For each event,
severity and study drug causality were assessed.
2.7. Statistical analysis
Statistical analysis was performed using SAS (SAS Software
Release 9.2, Cary, NC, USA). The primary and secondary
pharmacokinetic plasma parameters after logarithmic transforma-
tion were subjected to an Analysis of Variance (ANOVA).
Consistent with the one-sided tests for bioequivalence, 90%-
confidence intervals for the difference between drug formula-
tion least-squares means (LSM) were calculated for the log-
transformed parameter plasma AUC0–12h and plasma Cmax.
Plasma tmax, sputum pharmacokinetic and clinical parameters
were evaluated descriptively. With the assumption of a point
estimator of 95–105% and an intra-patient variability of CV of
34% for plasma AUC0–12h (based on the variance observed in a
preceding pharmacokinetic study [4]), 50 patients were sufficient
to show bioequivalence with a power of 80–90%. Assuming a
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randomized.
3. Results
3.1. Patient characteristics
Of the 64 screened patients, 58 patients qualified for study
participation were randomized (intent-to-treat population;
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Table 1
Demographic and basic characteristics of the intent-to-treat study population.
Demographics
All 4–13 years N13 years
Patients (N) 58 28 30
Sex
Male [n (%)] 25 (43) 15 (54) 10 (33)
Female [n (%)] 33 (57) 13 (46) 20 (67)
Age (years)
Mean ± SD 15.4 ± 6.81 10.0 ± 1.84 20.6 ± 5.52
Range 7–36 7–13 13–36
Weight (kg)
Mean ± SD 43.3 ± 13.9 32.1 ± 9.5 53.7 ± 7.8
Range 15.0–72.0 15.0–52.0 38.7–72.0
Height (cm)
Mean ± SD 152.6 ± 16.4 139.6 ± 13.5 164.6 ± 7.0
Range 113–182 113–164 151–182
Baseline characteristics
T100 TNS
Patients (N) 28 30
FEV1 % predicted
Mean ± SD 63.8 ± 17.1 64.2 ± 17.7
Range (min/max) 30.0/82.8 28.0/83.9
PA colony density (log10)
Mean ± SD 5.17 ± 3.018 5.30 ± 3.070
Range (min/max) 0.00/10.10 0.15/10.10
SD, standard deviation; FEV1, forced expiratory volume in 1 s; PA, Pseudomonas
aeruginosa.
Table 2
Plasma and sputum tobramycin pharmacokinetics at Day 28 after treatment with
T100 or TNS.
Pharmacokinetic parameter T100 TNS
Serum
AUC0–12h (μg/ml∗h)
All patients 5.78 ± 3.57 5.81 ± 3.10
4–13years 5.88 ± 3.48 6.13 ± 3.41
N13 years 5.70 ± 3.71 5.55 ± 2.86
Cmax (μg/ml)
All patients 1.27 ± 0.81 1.33 ± 0.76
4–13 years 1.35 ± 0.74 1.43 ± 0.84
N13 years 1.21 ± 0.86 1.26 ± 0.89
tmax (h)
All patients 0.80 ± 0.39 0.80 ± 0.31
4–13 years 0.80 ± 0.33 0.90 ± 0.33
N13 years 0.90 ± 0.43 0.80 ± 0.28
Sputum
AUC0–8h (mg/g*h)
All patients 1.18 ± 1.15 0.87 ± 0.80
4–13 years 1.25 ± 1.34 0.98 ± 1.00
N13 years 1.12 ± 1.00 0.78 ± 0.60
Cmax (mg/g)
All patients 1.95 ± 2.19 1.42 ± 1.51
4–13 years 1.87 ± 2.16 1.23 ± 1.48
N13 years 2.01 ± 2.25 1.57 ± 1.54
tmax (h)
All patients 0.38 ± 1.12 0.39 ± 1.16
4–13 years 0.59 ± 1.66 0.61 ± 1.70
N13 years 0.21 ± 0.12 0.22 ± 0.26
AUC, area under the concentration–time curve; Cmax, maximum tobramycin
concentration; tmax, time to Cmax. Values are arithmetic mean ± standard deviation.
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Plasma tobramycin pharmacokinetic parameters after a 4-week
treatment period are summarized in Table 2. Areas under the
plasma concentration–time curves from the first time point to the
time point of the last measured concentration are shown in Fig. 2.
Pre-treatment trough plasma tobramycin concentrations (C0)
were low for both drug/device combinations (approx. 0.15 μg/ml).
On treatment Day 28, the AUC0–12h was 5.78 ± 3.57 and
5.81 ± 3.10 μg/ml∗h for T100 and TNS, respectively (arithmetic
means ± SD). The corresponding peak plasma tobramycin
concentrations (Cmax) were 1.27 ± 0.81 and 1.33 ± 0.76 μg/ml.
The geometric mean ratios (T100:TNS) for Cmax and AUC0–12h
were 0.83 (90% CI 0.66, 1.04; p = 0.6101) and 0.85 (90% CI
0.68, 1.05; p = 0.1663), respectively. The accepted ranges for the
test:reference ratios are 0.75–1.33 for plasma Cmax and 0.80–
1.25 for plasma AUC. The mean tmax values were comparable
with 0.80 ± 0.39 h (T100) and 0.80 ± 0.31 h (TNS).
3.3. Sputum tobramycin concentrations
Sputum tobramycin pharmacokinetic parameters after a 4-week
treatment period are summarized in Table 2. Areas under the
sputum concentration–time curves from the first time point to
the time point of the last measured concentration are shown in
Fig. 2. On treatment Day 28, the AUC0–8h was 1.18 ± 1.15 and
0.87 ± 0.80 mg/g∗h for T100 and TNS, respectively (arithmeticmean ± SD). The corresponding peak sputum tobramycin con-
centrations (Cmax) were 1.95 ± 2.19 and 1.42 ± 1.51 mg/g. The
mean tmax values were comparable with 0.38 ± 1.12 h (T100)
and 0.39 ± 1.16 h (TNS).
3.4. Reduction of PA colony forming units
Treatment with tobramycin resulted in an overall reduction in
CFU density of P. aeruginosa, irrespective of the drug/device
combination. In general, the treatment effect was more pro-
nounced in the first compared to the second treatment period
(Fig. 3). During Treatment Period-1, a similar log10 CFU
reduction was achieved with T100 (−1.77 ± 2.74; difference
pre- vs. post-treatment: p = 0.0049) and TNS (1.70 ± 2.93;
difference pre- vs. post-treatment: p = 0.0020); after Treatment
Period-2, the reduction was −1.30 ± 2.55 (p = 0.012) and
0.12 ± 1.78 (p = 0.7341), respectively. There was no treatment
difference between T100 and TNS at the end of Treatment
Period-1 (p = 0.9245), but a statistically significant difference
was reached at the end of Treatment Period-2 (p = 0.0225).
3.5. Lung function (FEV1 % predicted)
The treatment effects regarding FEV1% predicted were similar
for both groups, T100 and TNS, during Treatment Period-1.
However, a positive treatment effect was also observed for T100
after Treatment Period-2 (Fig. 3). During Treatment Period-1, a
Fig. 2. Mean plasma (top) and sputum (bottom) tobramycin concentrations over time on Day 28 after administration of T100 (squares) or TNS (rhombi) in the overall
study population (PK Analysis Set). Bars represent the 95% confidence intervals.
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(8.20 ± 9.49%; difference pre- vs. post-treatment: p b 0.0001)
and TNS (4.80 ± 9.58%; difference pre- vs. post-treatment: p =
0.0132); after Treatment Period-2, the change was 2.40 ± 10.64%
(p = 0.2436) and −0.44 ± 8.10% (p = 0.7862), respectively. In
neither Treatment Period, the differences between the T100 and
TNS groups reached statistical significance (p[Treatment Period-1]:
0.1881; p[Treatment Period-2]: 0.2789).
3.6. Compliance and nebulisation times
Compliance to therapy of the patients was generally high in
both groups with 99% for T100 patients (as recorded by an
electronic Monitoring System of the device) and 99% for TNS
patients (as recorded in patient diaries). The time per nebulisationwas impressively reduced in the new T100 drug/device com-
bination (mean: 4.4 min) as compared to the standard TNS
combination (mean: 24.3 min).
3.7. Safety
Overall, 76 adverse events were reported in 29 patients (50%
of all patients) of the safety population under investigation
(n = 58). Twenty-nine patients experienced no AEs. Three AEs
were severe in intensity; all others were classified to be mild to
moderate. Thirty-two adverse events (approx. 42% of all AEs)
were considered to be related to the study drug, i.e. they were
defined as adverse drug reactions (ADRs). All of them were
classified as mild to moderate in intensity. In no case study,
medication had to be discontinued temporarily or permanently
Fig. 3. Top: Reduction of P. aeruginosa CFU calculated from beginning until end of each treatment cycle (T100: red; TNS: blank); *p b 0.05, and **p b 0.01.
Bottom: Change of FEV1 % predicted determined at the beginning and the end of each treatment cycle (T100: red; TNS: blank); *p b 0.01; and **p b 0.001. Bars
represent the standard deviations.
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recorded in 4 patients; the reason for seriousness was hos-
pitalisation in all cases. None of the SAEs was drug-related. No
fatality was observed. Six events were described as clinically
relevant increases in laboratory values (4 in one patient, who
discontinued TNS-treatment, and increase of LDH in another two
patients, one patient in the T100, one patient in the TNS group,
both continued the treatment). All of these abnormal parameters
were recorded as AEs, i.e. none of these were drug related. Any
other changes of laboratory values outside of the normal range
were assessed by the investigators as “not clinically significant”.
Bronchospasms occurred only in 2 patients under TNS (3.4% of
the patients) and were considered by the investigator as adverse
drug reactions. Audiology testing revealed two cases of tinnitus
in patients under T100 treatment (3.4% of all patients). Both
cases were mild in severity, transient and resolving shortly after
inhalation. One patient in the T100 group showed pathological
signs in pure tone audiometry measured by bone connectivity(highest value for left ear at 2 kHz was 35 dB). Pulmonary
exacerbation was observed in one patient only during the wash-out
phase after TNS treatment. This patient required treatment with
antibiotics which were prohibited as per study protocol and thus
was withdrawn from further study participation.
4. Discussion
The intent of this study was to demonstrate equivalence
of T100 not only to the standard-of-care treatment using TNS,
primarily regarding pharmacokinetics, but also to efficacy
and safety. In such case, the reduction of daily nebulisation
times of a concentrated tobramycin inhalation solution de-
livered via an efficient nebuliser based on eFlow technology
could be regarded as beneficial for the quality of life of CF
patients.
The study failed to demonstrate bioequivalence between the
treatments by prospective analysis plan. The point estimates
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the accepted bioequivalence ranges, whereas the lower confidence
levels were outside these ranges. Thus, the obtained pharmacoki-
netic results were indicative for a lower systemic burden of T100
versus TNS, whereas local pulmonary tobramycin concentrations
were found to be higher after inhalation of T100. These results
have to be interpreted carefully, as plasma concentrations of
tobramycin, and even more sputum concentrations, showed very
high inter- and intra-individual variability. Not only the T100 was
characterised by high coefficients of variation (62%), but also the
reference product TNS (53%), an experience already described by
others [5–8] who investigated tobramycin pharmacokinetics in CF
patients.
Inhaled tobramycin pharmacokinetic investigations in CF
patients are challenged mainly by five factors: (1) the CF
disease status significantly impacts the physical properties of
the mucus and lung morphology; (2) the breathing manoeuvres
of the patient exert influence on the drug deposition in the lung;
(3) the differences in device design and characteristics used for
drug delivery; (4) the high variability of tobramycin pharma-
cokinetics even when administered intravenously [9,10]; and
(5) the patient-individual capability to produce sputum.
Analyses of the investigated clinical parameters (CFU and
lung function) were consistent with respect to a concomitant
improvement of lung function as a function of decreasing PA
density: During the first treatment cycle both drugs provided a
similar reduction in density of PA colony forming units. This
effect could be repeated when administering T100 as the
second treatment whereas in patients receiving TNS as second
course such an effect was missing.
Improvement in lung function was observed for all lung
function parameters investigated and more pronounced in the
first than in the second treatment phase for both products. A
continuous decline in clinical efficacy is well known also from
the treatment with other antibiotics when administered in an
on-treatment/off-treatment schedule [11]. However, under T100
therapy in the second phase patients were able to reverse the
decline in lung function during the wash-out phase, whereas
this effect could not be observed under TNS therapy, suggesting
a carry-over effect of the T100 treatment. Treatment with
both products resulted in a comparable overall clinical efficacy,
leading to a reduction of PA density and an improvement of lung
function. The treatment effects are indicative of therapeutic
equivalence.
No significant or unexpected safety problem was associated
with the inhalation of tobramycin. All of the ADRs were of mild
to moderate intensity. In all cases the reason for seriousness of
SAEs was hospitalisation; none of the reported SAEs were related
to the study drug. There were no relevant safety findings as
indicated by physical examinations, vital sign measurements,
number of bronchospasms, audiometry, bronchospasms and
clinical laboratory evaluations. All laboratory values numerically
outside the reference range were not clinically significant. The
study provided no evidence that patients were posed on risk for
tobramycin in neither of the two treatment arms. Thus, treatment
with T100 and TNS can be regarded as comparable with respect
to the products' safety profiles.Beyond that, the study has shown a remarkably shorter
nebulisation time with the new T100 tobramycin solution
administered via a more efficient nebuliser handset compared
to TNS administered via a jet nebuliser. This reduction in
nebulisation time of twice 20 min daily may enhance the
patients' compliance in routine use and, as a consequence, the
therapeutic efficacy and safety of the antibiotic treatment.
In conclusion, the study failed to demonstrate systemic bio-
equivalence, an accepted surrogate for therapeutic equivalence
by regulatory bodies. Despite lower systemic burden, T100
treatment resulted in a similar efficacy and safety profile as TNS.
The new drug/device combination T100 (VANTOBRA/Tolero)
reduced the inhalation time impressively and thus may contribute
to an improvement of the quality of life for CF patients by
shortening their daily treatment burden. T100 may also present a
viable alternative with short treatment time for those patients who
cannot tolerate tobramycin dry powder inhalation.
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